Center of Functional and Diagnostic Imaging and Research, Department of Clinical and Nuclear Medicine, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
Gastro Unit, Medical Division, Copenhagen University Hospital Hvidovre, Hvidovre Denmark.
PLoS One. 2019 Aug 29;14(8):e0220697. doi: 10.1371/journal.pone.0220697. eCollection 2019.
The soluble urokinase plasminogen activator receptor (suPAR) is related to hepatic inflammation and fibrosis and has been suggested to participate in the development of liver cirrhosis. Therefore, the aim of the current study was to measure the concentration of suPAR in the hepatic vein of cirrhotic patients during a liver vein catheterization to identify a possible hepatic suPAR generation. Furthermore, we explored if suPAR levels were associated with the degree of cirrhosis and liver dysfunction.
We included 105 cirrhotic patients and 19 liver-healthy controls. Blood was sampled from the hepatic vein and the femoral artery and suPAR was measured by enzyme-linked immunosorbent assay.
We identified significantly higher median suPAR concentrations among the cirrhotic patients (7.2 ng/ml in the hepatic vein; 6.8 ng/ml in the femoral artery) compared to the controls (2.6 ng/ml, respectively, p-values <0.001). However, the median hepatic suPAR formation was 0.0 ng/ml in both groups. We observed significantly increasing suPAR levels according to higher Child classes (4.5 ng/ml, 6.9 ng/ml and 9.0 ng/ml, Child A, B, C respectively; p-value<0.001), and significantly higher median suPAR concentrations in patients with ascites versus patients without ascites (8.1 ng/ml versus 5.3 ng/ml, respectively, p-value<0.001). suPAR levels were significantly related to bilirubin (r = 0.48, p<0.001), the hepatic venous pressure gradient (r = 0.39, p<0.001), the cardiac index (r = 0.24, p = 0.02) and the plasma volume (r = 0.33, p = 0.001), whereas suPAR levels were significantly inversely related to albumin (r = -0.59, p<0.001), plasma coagulation factors (r-0.39, p<0.001), the mean arterial pressure (r = -0.28, p = 0.004), the systemic vascular resistance (r = 0.26, p = 0.007), the indocyanine green clearance (r = -0.51, p<0,001) and the galactose elimination capacity (r = -0.39, p<0.001).
We identified elevated suPAR concentration in cirrhotic patients, which correlated significantly with the degree of cirrhosis and liver failure, but we were not able to demonstrate hepatic suPAR generation per se. This suggests that further investigations of the source of suPAR in cirrhotic patients need to be undertaken.
可溶性尿激酶型纤溶酶原激活物受体(suPAR)与肝炎症和纤维化有关,并被认为参与了肝硬化的发展。因此,本研究的目的是在肝静脉导管插入术期间测量肝硬化患者肝静脉中 suPAR 的浓度,以确定可能存在的肝 suPAR 生成。此外,我们还探讨了 suPAR 水平是否与肝硬化和肝功能障碍的严重程度有关。
我们纳入了 105 例肝硬化患者和 19 例肝健康对照者。从肝静脉和股动脉采集血样,并通过酶联免疫吸附试验测量 suPAR。
与对照组(分别为 2.6ng/ml,p 值均<0.001)相比,我们发现肝硬化患者的中位 suPAR 浓度明显更高(肝静脉 7.2ng/ml;股动脉 6.8ng/ml)。然而,两组的中位肝 suPAR 生成均为 0.0ng/ml。我们观察到 suPAR 水平随着 Child 分级的升高而显著升高(Child A、B、C 分别为 4.5ng/ml、6.9ng/ml 和 9.0ng/ml,p 值均<0.001),且腹水患者的中位 suPAR 浓度明显高于无腹水患者(分别为 8.1ng/ml 和 5.3ng/ml,p 值均<0.001)。suPAR 水平与胆红素(r=0.48,p<0.001)、肝静脉压力梯度(r=0.39,p<0.001)、心指数(r=0.24,p=0.02)和血浆容量(r=0.33,p=0.001)显著相关,而与白蛋白(r=-0.59,p<0.001)、血浆凝血因子(r=-0.39,p<0.001)、平均动脉压(r=-0.28,p=0.004)、全身血管阻力(r=0.26,p=0.007)、吲哚菁绿清除率(r=-0.51,p<0.001)和半乳糖消除能力(r=-0.39,p<0.001)显著负相关。
我们发现肝硬化患者的 suPAR 浓度升高,且与肝硬化和肝功能衰竭的严重程度显著相关,但未能证明肝本身存在 suPAR 生成。这表明需要进一步研究肝硬化患者 suPAR 的来源。